BioSpace5d
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...
BioSpace5d
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
BETHESDA, Md., Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor ...
BioSpace6d
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...
BioSpace6d
Matwings Technology Raised Series A Funding of Tens of Millions USD to Redefine Protein Design
SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A ...
BioSpace6d
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
TOKYO--(BUSINESS WIRE)--#Astellas--Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement ...
BioSpace7d
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Daikichiro Kobayashi) announced the establishment of a local subsidiary ...
BioSpace8d
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
Research on New System Published in Nature Biomedical Engineering Platform Engineers T Cells to Make Them Less Susceptible to Tumor Evasion Published in Nature Biomedical Engineering LOS ...
BioSpace9d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
BioSpace9d
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
BioSpace9d
To Attract VC Dollars in 2025, Biopharma Must Bring the Data: Pitchbook
High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...
BioSpace9d
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
BioSpace9d
5 Companies That Celebrated First Approvals in 2024
Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...